Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

12.18EUR
11:35am EST
Change (% chg)

€-0.33 (-2.64%)
Prev Close
€12.51
Open
€12.51
Day's High
€12.63
Day's Low
€12.04
Volume
131,634
Avg. Vol
88,424
52-wk High
€19.90
52-wk Low
€8.62

ABS.PA

Chart for ABS.PA

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.76
Market Cap(Mil.): €475.43
Shares Outstanding(Mil.): 38.00
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 30.04 30.65
EPS (TTM): -0.81 -- --
ROI: -159.52 15.86 15.23
ROE: -- 16.96 16.56

BRIEF-Ab Science announces update on masitinib

* Announces the filing of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European medicines agency

Sep 29 2016

BRIEF-AB Science H1 net loss widens to 14.8 million euros

* H1 net loss of 14.8 million euros versus loss of 13.0 million euros ($14.49 million) year ago

Aug 31 2016

BRIEF-AB Science: Masitinib receives orphan drug designation in EU for ALS

* Announces that Masitinib receives from European Medicines Agency (EMA) orphan drug designation in the European Union for Amyotrophic Lateral Sclerosis (ALS) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 08 2016

BRIEF-Ab Science action plan following warning letter validated by FDA

* Announces that the FDA informed AB Science that it trusts the action plan implemented to address the FDA warning letter and to comply with FDA regulations Source text: http://bit.ly/29H6m3g Further company coverage: (Gdynia Newsroom)

Jul 14 2016

BRIEF-AB Science announces FDA approval compassionate use of masitinib in amyotrophic lateral sclerosis

* AB Science announces that FDA approves first compassionate use of masitinib in amyotrophic lateral sclerosis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 11 2016

BRIEF-Ab Science: Updates on marketing authorization application of masitinib

* Annouces that review of conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (als) will follow standard timeline of EMA

Jul 04 2016

Earnings vs. Estimates